Rhumbline Advisers Amylyx Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.62 - $2.71 $65,810 - $110,091	-40,624 Reduced 58.53%	28,779 $54,000
Q1 2024 May 09, 2024	BUY	$2.71 - $19.57 $3,035 - $21,918	1,120 Added 1.64%	69,403 $197,000
Q4 2023 Feb 08, 2024	SELL	$12.07 - $18.46 $8,171 - $12,497	-677 Reduced 0.98%	68,283 $1.01 Million
Q3 2023 Nov 09, 2023	BUY	$18.08 - $23.45 $15,639 - $20,284	865 Added 1.27%	68,960 $1.26 Million
Q2 2023 Aug 08, 2023	SELL	$20.98 - $31.42 $165,049 - $247,181	-7,867 Reduced 10.36%	68,095 $1.47 Million
Q1 2023 May 11, 2023	BUY	$27.71 - $40.93 $121,868 - $180,010	4,398 Added 6.15%	75,962 $2.23 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $766,687 - $1.01 Million	25,771 Added 56.28%	71,564 $2.64 Million
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $507,965 - $915,819	29,619 Added 183.13%	45,793 $1.29 Million
Q2 2022 Aug 11, 2022	BUY	$6.85 - $19.93 $110,791 - $322,347	16,174 New	16,174 $312,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.